Research programme: atherosclerosis vaccine - AFFiRiS

Drug Profile

Research programme: atherosclerosis vaccine - AFFiRiS

Alternative Names: ATH-05

Latest Information Update: 20 Jun 2014

Price : $50

At a glance

  • Originator AFFiRiS
  • Class Peptide vaccines
  • Mechanism of Action LDL receptor antagonists; PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Atherosclerosis

Most Recent Events

  • 20 Jun 2014 Preclinical trials in Atherosclerosis in Austria (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top